Literature DB >> 28721467

A Review of the Safety, Efficacy and Mechanisms of Delivery of Nasal Oxytocin in Children: Therapeutic Potential for Autism and Prader-Willi Syndrome, and Recommendations for Future Research.

Marilena M DeMayo1, Yun Ju C Song1, Ian B Hickie1, Adam J Guastella2.   

Abstract

In this article, we conduct a comprehensive review of existing evidence for the safety and therapeutic potential of intranasal oxytocin in pediatric populations. Unique considerations for dosing and delivery of oxytocin to the nasal passageway in pediatric populations and methods to promote adherence are reviewed. Intranasal oxytocin has been administered to 261 children in three open-label studies and eight randomized controlled trials. To date, the only published results in pediatric populations have focused on autism spectrum disorder (ASD) and Prader-Willi syndrome (PWS). Results regarding efficacy for improving social impairment in ASD are equivocal, partially due to mixed methodological designs, dosing regimens, and outcome measures. At present, there is no randomized controlled evidence that oxytocin provides benefit to individuals with PWS. There is no clear evidence of a link between oxytocin administration and any specific adverse event. Adverse events have been assessed using medical interviews, open reports, checklists, and physiological assessments. Adverse events reports have been largely classified as mild (n = 93), with few moderate (n = 9) or severe (n = 3) events reported. There were 35 additional adverse events reported, without severity ratings. Severe events, hyperactivity and irritability, occurred at first administration in both placebo and oxytocin groups, and subsided subsequent to discontinuation. We note that adverse event monitoring is inconsistent and often lacking, and reporting of its relationship to the study drug is poor. Only one study reported adherence data to suggest high adherence. Recommendations are then provided for the delivery of nasal sprays to the nasal passageway, monitoring, and reporting of efficacy, safety, and adherence for oxytocin nasal spray trials in pediatric populations.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28721467     DOI: 10.1007/s40272-017-0248-y

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  83 in total

Review 1.  A critical review of the influence of oxytocin nasal spray on social cognition in humans: evidence and future directions.

Authors:  Adam J Guastella; Adam J Graustella; Colin MacLeod
Journal:  Horm Behav       Date:  2012-01-11       Impact factor: 3.587

2.  Oxytocin enhances brain function in children with autism.

Authors:  Ilanit Gordon; Brent C Vander Wyk; Randi H Bennett; Cara Cordeaux; Molly V Lucas; Jeffrey A Eilbott; Orna Zagoory-Sharon; James F Leckman; Ruth Feldman; Kevin A Pelphrey
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

3.  Nucleus accumbens oxytocin and dopamine interact to regulate pair bond formation in female prairie voles.

Authors:  Y Liu; Z X Wang
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

4.  Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders.

Authors:  Adam J Guastella; Stewart L Einfeld; Kylie M Gray; Nicole J Rinehart; Bruce J Tonge; Timothy J Lambert; Ian B Hickie
Journal:  Biol Psychiatry       Date:  2009-11-07       Impact factor: 13.382

5.  Early intervention critical to autism treatment.

Authors:  Eric M Butter; Jacqueline Wynn; James A Mulick
Journal:  Pediatr Ann       Date:  2003-10       Impact factor: 1.132

Review 6.  How can we improve the assessment of safety in child and adolescent psychopharmacology?

Authors:  Benedetto Vitiello; Mark A Riddle; Laurence L Greenhill; John S March; Jerome Levine; Russell J Schachar; Howard Abikoff; Julie M Zito; James T McCracken; John T Walkup; Robert L Findling; James Robinson; Thomas B Cooper; Mark Davies; Elena Varipatis; Michael J Labellarte; Lawrence Scahill; Lisa Capasso
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2003-06       Impact factor: 8.829

7.  Social and communication development in toddlers with early and later diagnosis of autism spectrum disorders.

Authors:  Rebecca J Landa; Katherine C Holman; Elizabeth Garrett-Mayer
Journal:  Arch Gen Psychiatry       Date:  2007-07

8.  Changes in nasal cavity dimensions in children and adults by gender and age.

Authors:  Bolesław K Samoliński; Antoni Grzanka; Tomasz Gotlib
Journal:  Laryngoscope       Date:  2007-08       Impact factor: 3.325

9.  Barrier mechanisms in the developing brain.

Authors:  Norman R Saunders; Shane A Liddelow; Katarzyna M Dziegielewska
Journal:  Front Pharmacol       Date:  2012-03-29       Impact factor: 5.810

10.  Oxytocin for Male Subjects with Autism Spectrum Disorder and Comorbid Intellectual Disabilities: A Randomized Pilot Study.

Authors:  Toshio Munesue; Hiroyuki Nakamura; Mitsuru Kikuchi; Yui Miura; Noriyuki Takeuchi; Tokie Anme; Eiji Nanba; Kaori Adachi; Kiyotaka Tsubouchi; Yoshimichi Sai; Ken-Ichi Miyamoto; Shin-Ichi Horike; Shigeru Yokoyama; Hideo Nakatani; Yo Niida; Hirotaka Kosaka; Yoshio Minabe; Haruhiro Higashida
Journal:  Front Psychiatry       Date:  2016-01-21       Impact factor: 4.157

View more
  19 in total

1.  The New Statistics for Better Science: Ask How Much, How Uncertain, and What Else is Known.

Authors:  Robert J Calin-Jageman; Geoff Cumming
Journal:  Am Stat       Date:  2019-03-20       Impact factor: 8.710

2.  Binding Characteristics of Two Oxytocin Variants and Vasopressin at Oxytocin Receptors from Four Primate Species with Different Social Behavior Patterns.

Authors:  Jack H Taylor; Nancy A Schulte; Jeffrey A French; Myron L Toews
Journal:  J Pharmacol Exp Ther       Date:  2018-08-01       Impact factor: 4.030

Review 3.  Circuits for social learning: A unified model and application to Autism Spectrum Disorder.

Authors:  Marilena M DeMayo; Larry J Young; Ian B Hickie; Yun Ju C Song; Adam J Guastella
Journal:  Neurosci Biobehav Rev       Date:  2019-09-24       Impact factor: 8.989

4.  Chronic oxytocin administration as a tool for investigation and treatment: A cross-disciplinary systematic review.

Authors:  Marilyn Horta; Kathryn Kaylor; David Feifel; Natalie C Ebner
Journal:  Neurosci Biobehav Rev       Date:  2019-10-21       Impact factor: 8.989

5.  No side-effects of single intranasal oxytocin administration in middle childhood.

Authors:  Martine W F T Verhees; Janne Houben; Eva Ceulemans; Marian J Bakermans-Kranenburg; Marinus H van IJzendoorn; Guy Bosmans
Journal:  Psychopharmacology (Berl)       Date:  2018-06-18       Impact factor: 4.530

6.  The Importance of Experimental Investigation of the CNS Oxytocin System.

Authors:  Kelsie A Boulton; Adam J Guastella
Journal:  Methods Mol Biol       Date:  2022

7.  Oxytocin as an adolescent treatment for methamphetamine addiction after early life stress in male and female rats.

Authors:  Jennifer L Cornish; Nicholas A Everett; Sarah J Baracz; Katherine J Robinson; Amanda L Wright; Anita J Turner; Iain S McGregor
Journal:  Neuropsychopharmacology       Date:  2022-05-17       Impact factor: 8.294

Review 8.  Oxytocin in the Male Reproductive Tract; The Therapeutic Potential of Oxytocin-Agonists and-Antagonists.

Authors:  Beatrix Stadler; Michael R Whittaker; Betty Exintaris; Ralf Middendorff
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-22       Impact factor: 5.555

Review 9.  Metabolic Effects of Oxytocin.

Authors:  Shana E McCormack; James E Blevins; Elizabeth A Lawson
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

10.  Intranasal oxytocin increases heart-rate variability in men at clinical high risk for psychosis: a proof-of-concept study.

Authors:  Paolo Fusar-Poli; Yannis Paloyelis; Daniel Martins; Cathy Davies; Andrea De Micheli; Dominic Oliver; Alicja Krawczun-Rygmaczewska
Journal:  Transl Psychiatry       Date:  2020-07-12       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.